EXL01 Clinical Trials
4 recruitingDrug
Phase 24Phase 12
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
Clostridioides Difficile InfectionRecurrent Infection
Hospices Civils de Lyon56 enrolled9 locationsNCT06306014
Recruiting
Phase 1Phase 2
EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.
Non-small Cell Lung Cancer
University Hospital, Lille21 enrolled1 locationNCT06448572
Recruiting
Phase 2
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
Gastric Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group120 enrolled37 locationsNCT06253611
Recruiting
Phase 2
Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma
Hepatocellular Carcinoma
Center Eugene Marquis34 enrolled6 locationsNCT06551272